SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug Target
TORONTO, ONTARIO –August 26, 2021, Satellos Bioscience Inc. (“Satellos”) (TSX-V:MSCL), announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy (“Duchenne”).
Satellos scientists are developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company’s drug candidates regulate the activity of PTP-X, the codename for an enzyme which Satellos discovered to be involved in controlling muscle stem cell function, allowing the stem cells to properly divide and repair damaged tissue that accumulates in the muscles of Duchenne patients. “These findings represent a huge step forward in our scientific efforts to design highly potent small molecule inhibitors of PTP-X” said Frank Gleeson, CEO of Satellos. “Until this point a reliable, high-quality image of our drug target has simply not been available. With this key foundational piece now in place, we have the potential to accelerate our lead optimization program with our already potent compounds and achieve one of our key goals, namely, the timely nomination of a development candidate.”
Mr. Gleeson added: “We also wish to express our gratitude to our partners at Parent Project Muscular Dystrophy (“PPMD”), a leading US based non-profit organization dedicated to the fight to end Duchenne for over 25 years. PPMD’s confidence in and financial support of Satellos has been invaluable to enabling us to achieve this significant drug discovery breakthrough.”
“PPMD is delighted to see this tangible progress which, among other developments by Satellos triggered our recent milestone payment, bringing our current investment to US $1,000,000” said Pat Furlong, Founder and CEO of PPMD. “Our venture investment strategy is guided by our commitment to complete critical studies needed to advance investigational products to the clinic. We look forward to Satellos continuing to advance their compelling science toward selecting a drug candidate suitable for testing in people living with Duchenne.”
“We are thrilled to have identified the specific conditions that must be met in order to generate this high quality, 1.85Å resolution crystal structure of PTP-X and have already begun the process of generating co-crystals with our small molecule drug candidates, meant to pinpoint precisely where they bind the target” said Dr. Sridhar Narayan, VP of Drug Discovery and Program Leadership at Satellos. “Generation of co-crystal structures will significantly boost our ability to conduct design-make-test cycles critical for lead optimization and achieving the most desirable balance of drug like properties as quickly as possible. This work was carried out in collaboration with our fantastic structural biology partners Wuxi Biortus Biosciences Co. Ltd. (Jiangsu, China) and IniXium Inc. (Laval, QC) whom we wish to acknowledge.”
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity — a process that balances replenishment of muscle stem cells and production of specialized tissue cells— can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos’ lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenXTM, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage programs codenamed iCo-008 and iCo-019 as a result of its reverse takeover of iCo Therapeutics Inc. Founded in 2018, Satellos is headquartered in Canada. For more information about Satellos’ regenerative therapeutic discovery platform, development programs, or licensing opportunities for iCo assets please contact Ryan Mitchell, PhD, Director – Business Development @ [email protected] or visit Satellos.com.
For more information about Satellos contact: Frank Gleeson, President and Chief Executive Officer, Satellos Bioscience Inc. at [email protected]
Duchenne muscular dystrophy (“Duchenne”) is the most common fatal genetic disorder, slowly and progressively robbing people of their muscle strength and function. Diagnosed in childhood, affecting approximately one in 5,000 live male births, Duchenne is caused by a change in the dystrophin gene. In people living with Duchenne, it was discovered by Dr. Michael Rudnicki, the scientific founder of Satellos, that muscle stem cells are severely compromised in their ability to create muscle progenitor cells which repair injured muscle. As a result, people with Duchenne are unable to keep up with the continuous damage to their muscles throughout life.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUYANY SECURITIES IN ANYJURISDICTION, NOR SHALL THERE BE ANY OFFER, SALE, OR SOLICITATION OF SECURITIES IN ANYJURISDICTION IN WHICH SUCH OFFER, SALE, OR SOLICITATION WOULD BE UNLAWFUL.
THE SECURITIES ISSUED IN CONNECTION WITH THE ARRANGEMENT and concurrent financing HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE “1933 ACT’) AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT. THE RESULTING ISSUER INTENDS TO ISSUE SUCH SECURITIES PURSUANT TO THE EXEMPTION FROM REGISTRATION SET FORTH IN SECTION 3(a)(10) OF THE 1933 ACT.
Notice on forward-looking statements:
This release includes forward-looking information or forward-looking statements within the meaning of Canadian securities laws, the 1933 Act, the U.S. Securities TSXV Act of 1934 and the U.S. Private Securities Litigation Reform Act of 1995 regarding Satellos and its business, which may include, but are not limited to, statements with respect to the ability to obtain regulatory approvals, the final approval of the TSXV and issuance of the final exchange bulletin, the use of proceeds from the Concurrent Financing, Satellos’ technologies and drug development plans, the timeline to commence clinical trial testing in humans and evaluation plans for drug molecules, the timeline for Satellos Shares to resume trading. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may’, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, market conditions, economic factors, management’s ability to manage and to operate the business of the company and the equity markets generally. Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.